Daniel A Guthy

发表

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Hans Bitter, Joerg Kallen, Pascal Furet, 2015, eLife.

Abstract 3748: NVP-BYL719, a novel PI3Kalpha selective inhibitor with all the characteristics required for clinical development as an anti-cancer agent

C. Schnell, F. Hofmann, S. Brachmann, 2012 .

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014, Molecular Cancer Therapeutics.

Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.

P. Furet, G. Caravatti, T. Zoller, 2015, Bioorganic & medicinal chemistry letters.

Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.

C. Schnell, P. Furet, F. Blasco, 2015, Bioorganic & medicinal chemistry letters.

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

W. Sellers, A. Kauffmann, F. Hofmann, 2012, Molecular Cancer Therapeutics.

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

W. Sellers, D. Fabbro, Christopher J. Wilson, 2011, Molecular Cancer Therapeutics.

Modulation of drug resistance by artificial transcription factors

D. Erdmann, C. Barbas, B. Torbett, 2008, Molecular Cancer Therapeutics.

Identification and characterization of NVP-BKM 120 , an orally available pan class I PI 3-Kinase inhibitor

W. Sellers, D. Fabbro, R. Schlegel, 2011 .

Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival

T. Radimerski, D. Guthy, R. Andraos, 2011, BMC Cancer.

Discovery of a novel tricyclic 4H-thiazolo[5',4':4,5]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3Kα inhibitor with high PI3K isoform selectivity and potent cellular activity.

P. Furet, C. Fritsch, R. Mah, 2015, Bioorganic & medicinal chemistry letters.

Small Molecule Therapeutics Characterization of the Novel and Speci fi c PI 3 K a Inhibitor NVP-BYL 719 and Development of the Patient Strati fi cation Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014 .

Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

C. Schnell, P. Furet, F. Blasco, 2022, Journal of medicinal chemistry.

Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.

W. Sellers, E. Billy, C. Schnell, 2016, Cancer research.

Antibody-based arrays in disease proteomics

H. Voshol, Daniel A Guthy, 2015 .

Genetic reprogramming of tumor cells by zinc finger transcription factors.

D. Erdmann, B. González, C. Barbas, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer

M. Ristov, Dario Sterker, D. Guthy, 2017, Cancer Chemotherapy and Pharmacology.

EndoBind detects endogenous protein-protein interactions in real time

Frederick J. King, A. Orth, L. Miraglia, 2021, Communications Biology.

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

N. Ostermann, C. Schnell, Toshio Shimizu, 2022, Cancer discovery.

Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models

D. Erdmann, N. Ostermann, C. Schnell, 2021, Poster Presentations - Proffered Abstracts.

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

R. Tiedt, D. Guthy, C. Scheufler, 2019, ACS medicinal chemistry letters.

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.

N. Ostermann, R. Wilcken, S. Brachmann, 2022, Journal of medicinal chemistry.

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

W. Sellers, Philipp Holzer, P. Furet, 2015, eLife.

Antibody-based arrays in disease proteomics

Daniel A Guthy, Hans Voshol, 2015 .

Antibody-based arrays in disease proteomics

Daniel A Guthy, Hans Voshol, 2015 .

Antibody-based arrays in disease proteomics

Daniel A Guthy, Hans Voshol, 2015 .

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.

Philipp Holzer, R. Tiedt, G. Caravatti, 2016, ACS medicinal chemistry letters.